These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 29089267

  • 1. Quadruple, sequential, and concomitant first-line therapies for H. pylori eradication: a prospective, randomized study.
    De Francesco V, Pontone S, Bellesia A, Serviddio G, Panetta C, Palma R, Zullo A.
    Dig Liver Dis; 2018 Feb; 50(2):139-141. PubMed ID: 29089267
    [Abstract] [Full Text] [Related]

  • 2. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice.
    Fiorini G, Zullo A, Saracino IM, Gatta L, Pavoni M, Vaira D.
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):621-625. PubMed ID: 29481383
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial.
    Su J, Zhou X, Chen H, Hao B, Zhang W, Zhang G.
    Medicine (Baltimore); 2017 Feb; 96(7):e5859. PubMed ID: 28207505
    [Abstract] [Full Text] [Related]

  • 4. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
    Gisbert JP, Romano M, Gravina AG, Solís-Muñoz P, Bermejo F, Molina-Infante J, Castro-Fernández M, Ortuño J, Lucendo AJ, Herranz M, Modolell I, Del Castillo F, Gómez J, Barrio J, Velayos B, Gómez B, Domínguez JL, Miranda A, Martorano M, Algaba A, Pabón M, Angueira T, Fernández-Salazar L, Federico A, Marín AC, McNicholl AG.
    Aliment Pharmacol Ther; 2015 Apr; 41(8):768-75. PubMed ID: 25703120
    [Abstract] [Full Text] [Related]

  • 5. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
    Fu W, Song Z, Zhou L, Xue Y, Ding Y, Suo B, Tian X, Wang L.
    Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
    [Abstract] [Full Text] [Related]

  • 6. Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice.
    Zullo A, De Francesco V, Bellesia A, Vassallo R, D'Angelo A, Scaccianoce G, Sacco R, Bresci G, Eramo A, Tanzilli A, Ridola L, Alvaro D, Londoni C, Brambilla G, Manta R, Di Ciaula A, Portincasa P.
    J Gastrointestin Liver Dis; 2017 Sep; 26(3):225-229. PubMed ID: 28922433
    [Abstract] [Full Text] [Related]

  • 7. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study.
    Zullo A, Scaccianoce G, De Francesco V, Ruggiero V, D'Ambrosio P, Castorani L, Bonfrate L, Vannella L, Hassan C, Portincasa P.
    Clin Res Hepatol Gastroenterol; 2013 Dec; 37(6):647-50. PubMed ID: 23747131
    [Abstract] [Full Text] [Related]

  • 8. Comparison Between Sequential Therapy and Modified Bismuth-Included Quadruple Therapy for Helicobacter pylori Eradication in Chinese Patients.
    Yang X, Tan P, Song L, Lu Z.
    Am J Ther; 2016 Dec; 23(6):e1436-e1441. PubMed ID: 25923229
    [Abstract] [Full Text] [Related]

  • 9. Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy.
    Hsu PI, Chen WC, Tsay FW, Shih CA, Kao SS, Wang HM, Yu HC, Lai KH, Tseng HH, Peng NJ, Chen A, Kuo CH, Wu DC, Taiwan Acid-Related Disease (TARD) Study Group.
    Helicobacter; 2014 Feb; 19(1):74-9. PubMed ID: 24033865
    [Abstract] [Full Text] [Related]

  • 10. 14 day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: a multicentre, non-inferiority, randomized trial.
    Liou JM, Chen CC, Fang YJ, Chen PY, Chang CY, Chou CK, Chen MJ, Tseng CH, Lee JY, Yang TH, Chiu MC, Yu JJ, Kuo CC, Luo JC, Hsu WF, Hu WH, Tsai MH, Lin JT, Shun CT, Twu G, Lee YC, Bair MJ, Wu MS, Members of the Taiwan Gastrointestinal Disease and Helicobacter Consortium.
    J Antimicrob Chemother; 2018 Sep 01; 73(9):2510-2518. PubMed ID: 29846605
    [Abstract] [Full Text] [Related]

  • 11. Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area.
    Georgopoulos SD, Xirouchakis E, Martinez-Gonzales B, Zampeli E, Grivas E, Spiliadi C, Sotiropoulou M, Petraki K, Zografos K, Laoudi F, Sgouras D, Mentis A, Kasapidis P, Michopoulos S.
    Eur J Intern Med; 2016 Jul 01; 32():84-90. PubMed ID: 27134145
    [Abstract] [Full Text] [Related]

  • 12. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
    Liou JM, Jiang XT, Chen CC, Luo JC, Bair MJ, Chen PY, Chou CK, Fang YJ, Chen MJ, Chen CC, Lee JY, Yang TH, Yu CC, Kuo CC, Chiu MC, Chen CY, Shun CT, Hu WH, Tsai MH, Hsu YC, Tseng CH, Chang CY, Lin JT, El-Omar EM, Wu MS, Taiwan Gastrointestinal Disease and Helicobacter Consortium.
    Lancet Gastroenterol Hepatol; 2023 Mar 01; 8(3):228-241. PubMed ID: 36549320
    [Abstract] [Full Text] [Related]

  • 13. Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
    Zhang D, Ke L, Ni Z, Chen Y, Zhang LH, Zhu SH, Li CJ, Shang L, Liang J, Shi YQ.
    Medicine (Baltimore); 2017 Aug 01; 96(32):e7697. PubMed ID: 28796053
    [Abstract] [Full Text] [Related]

  • 14. Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial.
    Lu B, Wang J, Li J, Liu L, Chen Y.
    Helicobacter; 2019 Apr 01; 24(2):e12566. PubMed ID: 30780194
    [Abstract] [Full Text] [Related]

  • 15. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial.
    Hsu PI, Tsai FW, Kao SS, Hsu WH, Cheng JS, Peng NJ, Tsai KW, Hu HM, Wang YK, Chuah SK, Chen A, Wu DC.
    Am J Gastroenterol; 2017 Sep 01; 112(9):1374-1381. PubMed ID: 28719592
    [Abstract] [Full Text] [Related]

  • 16. Sequential therapy for first-line Helicobacter pylori eradication: 10- or 14-day regimen?
    Zullo A, Fiorini G, Scaccianoce G, Portincasa P, De Francesco V, Vassallo R, Urban F, Monica F, Mogavero G, Amato A, Vaira D.
    J Gastrointestin Liver Dis; 2019 Mar 01; 28(1):11-14. PubMed ID: 30851166
    [Abstract] [Full Text] [Related]

  • 17. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
    Song Z, Zhou L, Zhang J, He L, Bai P, Xue Y.
    Dig Liver Dis; 2016 May 01; 48(5):506-511. PubMed ID: 26847964
    [Abstract] [Full Text] [Related]

  • 18. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance.
    Long X, Chen Q, Yu L, Liang X, Liu W, Lu H.
    Helicobacter; 2018 Jun 01; 23(3):e12485. PubMed ID: 29696736
    [Abstract] [Full Text] [Related]

  • 19. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment.
    Chen Q, Long X, Ji Y, Liang X, Li D, Gao H, Xu B, Liu M, Chen Y, Sun Y, Zhao Y, Xu G, Song Y, Yu L, Zhang W, Liu W, Graham DY, Lu H.
    Aliment Pharmacol Ther; 2019 Jun 01; 49(11):1385-1394. PubMed ID: 31020673
    [Abstract] [Full Text] [Related]

  • 20. Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.
    Gisbert JP, Barrio J, Modolell I, Molina-Infante J, Aisa AP, Castro-Fernández M, Rodrigo L, Cosme A, Gisbert JL, Fernández-Bermejo M, Marcos S, Marín AC, McNicholl AG.
    Dig Dis Sci; 2015 Feb 01; 60(2):458-64. PubMed ID: 25236423
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.